Examkin

Question

Difficulty: HardPediatric Genetic and Metabolic Disorders

An 8-month-old infant, recently immigrated from a rural region without a universal newborn screening program, is brought to the pediatric clinic for evaluation of developmental delay. The parents report that the infant has not yet started to sit unsupported, roll over, or babble. On physical examination, the infant has noticeably lighter skin and hair pigmentation compared to both biological parents, a diffuse eczematous rash on the flexor surfaces, and a distinct 'musty' body odor. A presumptive diagnosis of a metabolic disorder is made. Arrange the following steps in the most appropriate chronological sequence for the comprehensive evaluation and lifespan management of this patient's condition, from the immediate next diagnostic step to adulthood.

  1. 1Quantitative plasma amino acid analysis to confirm the presence of hyperphenylalaninemia
  2. 2Assessment of the urine pterin profile and dihydropteridine reductase activity
  3. 3Implementation of a strictly controlled, lifelong phenylalanine-restricted dietary regimen
  4. 4Continuous childhood surveillance for executive function deficits and behavioral issues
  5. 5Preconception counseling regarding the prevention of fetal cardiac defects and microcephaly

Answer

The correct chronological sequence is: 1) Quantitative plasma amino acid analysis, 2) Assessment of urine pterin profile, 3) Implementation of a phenylalanine-restricted diet, 4) Continuous childhood surveillance for executive function deficits, 5) Preconception counseling.
The sequence follows the logical and chronological clinical pathway for a newly diagnosed metabolic disorder: 1) Initial biochemical confirmation of the abnormality (hyperphenylalaninemia). 2) Differentiation of the specific molecular etiology (PAH vs. BH4 deficiency) prior to finalizing the lifelong treatment plan. 3) Implementation of the primary therapy (Phe-restricted diet). 4) Routine pediatric monitoring for known childhood complications (executive dysfunction). 5) Anticipatory guidance for known adult complications (teratogenicity of maternal PKU).

Step-by-Step Solution

1
Analyze the clinical presentation to identify the underlying metabolic disorder.
The combination of developmental delay, hypopigmentation, eczema, and a musty body odor in an unscreened infant is the classic presentation of Phenylketonuria (PKU).
Recognizing the disease is necessary to determine the specific diagnostic and management pathway.
2
Determine the initial diagnostic sequence for suspected PKU.
The first step is confirming hyperphenylalaninemia (Item 1). Immediately following confirmation, the etiology must be differentiated between a PAH enzyme defect and a BH4 cofactor defect (Item 2).
Missing a BH4 deficiency leads to severe, progressive neurological damage even if a phenylalanine-restricted diet is implemented, because BH4 is also required for serotonin and dopamine synthesis.
3
Identify the primary therapeutic intervention.
Once diagnosed, the patient requires the lifelong implementation of a phenylalanine-restricted medical diet (Item 3).
Dietary restriction is the cornerstone of preventing ongoing neurotoxicity in classic PKU.
4
Order the long-term complication screening and management steps according to the patient's lifespan.
Childhood neuropsychological surveillance (Item 4) occurs before adult preconception counseling for maternal PKU syndrome (Item 5).
This establishes the chronological continuum of care from acute pediatric diagnosis to adult preventative medicine.

Key Concept

The comprehensive lifespan management of Phenylketonuria (PKU) includes confirming hyperphenylalaninemia, ruling out BH4 cofactor deficiency, initiating a lifelong Phe-restricted diet, monitoring for childhood neurodevelopmental sequelae, and providing adult preconception counseling to prevent maternal PKU syndrome.
Estimated Time:1m 30s
Rate this question

Topics

Pediatric Genetic and Metabolic Disorders

More questions from this topic